Titan Pharmaceuticals (Titan Pharmaceuticals) GF Value Rank : 0 (As of May. 19, 2024)

View and export this data going back to 1996. Start your Free Trial

What is Titan Pharmaceuticals GF Value Rank?

Titan Pharmaceuticals has the GF Value Rank of 0.

The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

Titan Pharmaceuticals GF Value Rank Related Terms

Thank you for viewing the detailed overview of Titan Pharmaceuticals's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Titan Pharmaceuticals (Titan Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Titan Pharmaceuticals Inc (NAS:TTNP) » Definitions » GF Value Rank

Comparable Companies

Traded in Other Exchanges

TN70:Germany

Address

400 Oyster Point Boulevard, Suite 505, South San Francisco, CA, USA, 94080

Website

https://www.titanpharm.com

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was the Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine.

Executives

Seow Gim Shen	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
Sire Group Ltd.	10 percent owner	NO. 4, FRANKY BUILDING, PROVIDENCE INDUSTRIAL ESTATE, MAHE T2 00000
David Natan	director	11190 BISCAYNE BLVD, MIAMI FL 33181
Matthew Charles Mcmurdo	director	1047 SEWARD AVE., WESTFIELD NJ 07090
Peter Louis Chasey	director	3295 N. FORT APACHE ROAD, STE. 110, LAS VEGAS NV 89129
Eric Howard Greenberg	director	710 CARLYLE ST, WOODMERE NY 11598
Avraham Ben-tzvi	director	44 ZAYT SHEMEN ST., FLAT 4, EFRAT L3 9045544
Katherine Beebe	director, officer: President and COO	400 OYSTER POINT BLVD, SUITE 505, SOUTH SAN FRANCISCO CA 94080
Choon Hau Choong	10 percent owner	NO. 23 LORONG TERUBONG RIA 2,, PAYA TERUBONG, GEORGE TOWN N8 11060
David E. Lazar	director, 10 percent owner, officer: Chief Executive Officer	VILLA 1, 14-43RD STREET, JUMEIRAH 2, DUBAI C0 00000
Activist Investing Llc	other: Member of 10% owner group	1185 AVENUE OF THE AMERICAS, 3RD FLOOR., NEW YORK NY 10036
Joseph A Akers	director	630 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10111
James R Mcnab	director	C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Marc Rubin	director, officer: Executive Chairman	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Dane Hallberg	officer: See Remarks	400 OYSTER POINT BLVD., SUITE 505, SOUTH SAN FRANCISCO CA 94080